Farrell Simon - 20 Jun 2023 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Commercial Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Issuer symbol
TRVI
Transactions as of
20 Jun 2023
Net transactions value
+$3,194
Form type
4
Filing time
21 Jun 2023, 16:00:12 UTC
Previous filing
08 Mar 2023
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $3,194 +6,250 +16% $0.5110* 45,650 20 Jun 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -6,250 -11% $0.000000 50,000 20 Jun 2023 Common Stock 6,250 $0.5110 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.